Tovecimig Demonstrates Statistically Significant PFS Benefit but misses the OS benefit in COMPANION-002 Ph 2/3 Study in Patients with Biliary Tract Cancer May 6, 2026
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) May 6, 2026
Ph 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful PFS Improvement in PIK3CA Mutant Cohort May 6, 2026
FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer May 6, 2026
Huahui Health and BeOne Medicines Enter into a Global Exclusive Option, License and Collaboration Agreement for Innovative Oncology Drug HH160 May 6, 2026
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel May 6, 2026
DMC recommends halting Ph 3 FLASH2 trial of HyBryt (Synthetic Hypericin) in the treatment of CTCL patients post interim efficacy analysis May 6, 2026
Journal of Clinical Oncology Publishes Final Results of Duvelisib PRIMO Ph 2 Trial in R/R Peripheral T-cell Lymphoma May 6, 2026
Positive Ph 2a Data with Namodenoson in Pancreatic Cancer Reported; 35% of Patients Remain on Therapy, Including One Beyond 16 Months May 6, 2026
Ph 2/3 Clinical Trial Application submitted to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer May 6, 2026
US FDA Accepts NDA for Zipalertinib for the Treatment of Locally Advanced or Metastatic NSCLC with EGFR Exon 20 Insertion Mutations May 6, 2026
US FDA RMAT Designation Granted to Orca-Q® for the Treatment of High-Risk Hematologic Malignancies May 6, 2026
FDA ODAC didn’t reach a majority vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR+ve HER2neg breast cancer May 6, 2026
NDA Submission initiated from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence RTOR Program May 6, 2026
